Dr. Siddharth Kaul, MD
Neurology (Neurology Physician)
12266 De Paul Dr Ste 100
Bridgeton, MO 63044
Who else practices at this address →
St. Louis County includes dental (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 360
Licensed in Texas since 2023, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
OR license MD221827 · FL license ME161484 · IL license 125-055311 · MO license 2012009717 · TX license U3562 (first issued 2023; active) -
Hospitalist Physician
FL license ME161484
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ssm Health St Mary's Hospital - St Louis Saint Louis, MO
- Ssm Health Depaul Hospital St Louis Bridgeton, MO
- Ssm St Joseph Health Center Saint Charles, MO
- Ssm St Joseph Hospital West Lake Saint Louis, MO
- Ssm St Clare Health Center Fenton, MO
Medical groups
- Baptist Health Medical Group Inc (2,472 clinicians)
- Ssm Medical Group Inc (568 clinicians)
- Piedmont Hospitalist Physicians LLC (508 clinicians)
- Virtual Neurology LLC (164 clinicians)
- Virtual Neurology Texas PLLC (152 clinicians)
- Virtual Neurology PC (90 clinicians)
- Telespecialists North Carolina Neurology Services PLLC (37 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 360
- Services billed
- 667
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 209 | 120 |
| Established patient office or other outpatient visit, 30-39 minutes | 117 | 92 |
| Measurement of brain wave activity (eeg), awake and drowsy | 91 | 85 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 70 | 68 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 61 | 61 |
| Established patient office or other outpatient visit, 40-54 minutes | 59 | 46 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 48 | 18 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 34 | 20 |
| Telehealth consultation, critical care, initial , physicians typically spend 60 minutes communicating with the patient and providers via telehealth | 20 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Bridgeton, MO | 232 |
| Butalbital-Acetaminophen-Caffe (butalb/acetaminophen/caffeine) Other prescribers in Bridgeton, MO | 131 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Bridgeton, MO | 128 |
| Clonazepam Other prescribers in Bridgeton, MO | 116 |
| Levetiracetam Other prescribers in Bridgeton, MO | 113 |
| Sumatriptan Succinate Other prescribers in Bridgeton, MO | 98 |
| Nortriptyline Hcl Other prescribers in Bridgeton, MO | 94 |
| Tizanidine Hcl Other prescribers in Bridgeton, MO | 85 |
| Rizatriptan (rizatriptan benzoate) Other prescribers in Bridgeton, MO | 75 |
| Quetiapine Fumarate Other prescribers in Bridgeton, MO | 72 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 122 payments worth $57,590 in total to this clinician.
| AbbVie Inc. | $29,567 |
|---|---|
| Eisai Inc. | $10,903 |
| Pfizer Inc. | $9,814 |
| Axsome Therapeutics, Inc. | $6,839 |
| Neurocrine Biosciences, Inc. | $399 |
| Merck Sharp & Dohme LLC | $67.50 |
| Compensation for services other than consulting (speaking, faculty) | $35,831 |
|---|---|
| Speaking at a medical education program | $7,240 |
| Honoraria | $6,525 |
| Travel and Lodging | $4,304 |
| Food and Beverage | $2,707 |
| Consulting Fee | $983 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $4,200 |
| AbbVie Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,675 |
| Pfizer Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| Pfizer Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| Pfizer Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| AbbVie Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $2,756 |
| AbbVie Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $2,625 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $2,625 |
| AbbVie Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $2,625 |
| AbbVie Inc. Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $2,625 |
All 30 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| AbbVie Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $2,625 |
| Axsome Therapeutics, Inc. Nov 19, 2025 | Honoraria Symbravo · Neurology | $2,025 |
| Pfizer Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| Pfizer Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,150 |
| Eisai Inc. Nov 18, 2025 | Consulting Fee Leqembi · Neurology | $800 |
| Axsome Therapeutics, Inc. Sep 29, 2025 | Honoraria Symbravo · Neurology | $1,350 |
| Eisai Inc. Sep 18, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,000 |
| Eisai Inc. Sep 18, 2025 | Speaking at a medical education program Leqembi · Neurology | $400 |
| AbbVie Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,675 |
| AbbVie Inc. Aug 12, 2025 | Travel and Lodging QULIPTA · NEUROSCIENCE · travel to FARMINGTON, MO · in-kind | $960 |
| AbbVie Inc. Aug 11, 2025 | Compensation for services other than consulting (speaking, faculty) UBRELVY · NEUROSCIENCE | $2,625 |
| Axsome Therapeutics, Inc. Jul 29, 2025 | Honoraria Symbravo · Neurology | $2,025 |
| Axsome Therapeutics, Inc. Jul 23, 2025 | Honoraria Symbravo · Neurology | $1,125 |
| AbbVie Inc. May 28, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $4,200 |
| AbbVie Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $2,625 |
| Eisai Inc. May 9, 2025 | Consulting Fee Leqembi · Neurology | $183 |
| AbbVie Inc. May 2, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $2,625 |
| AbbVie Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $2,756 |
| AbbVie Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) BOTOX · NEUROSCIENCE | $2,625 |
| Eisai Inc. Apr 7, 2025 | Travel and Lodging Leqembi · Neurology · travel to Mattoon, IL | $1,350 |
| Eisai Inc. Apr 3, 2025 | Speaking at a medical education program Leqembi · Neurology | $2,190 |
| Eisai Inc. Apr 3, 2025 | Speaking at a medical education program Leqembi · Neurology | $913 |
| AbbVie Inc. Mar 29, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to DALLAS, TX · in-kind | $631 |
| AbbVie Inc. Mar 29, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to DALLAS, TX · in-kind | $327 |
| Eisai Inc. Jan 31, 2025 | Travel and Lodging Leqembi · Neurology · travel to Mattoon, IL | $1,037 |
| Eisai Inc. Jan 30, 2025 | Speaking at a medical education program Leqembi · Neurology | $1,095 |
| Eisai Inc. Jan 30, 2025 | Speaking at a medical education program Leqembi · Neurology | $913 |
| Eisai Inc. Jan 29, 2025 | Speaking at a medical education program Leqembi · Neurology | $730 |
| AbbVie Inc. Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $2,625 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $1,184,967 in research payments for these studies, mostly to the institutions running them.
- A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT06653153 - A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
H. Lundbeck A S · Completed · NCT06323928 - An interventional phase 1B randomized doubleblind sponsoropen placebocontrolled study to investigate the safety tolerability and pharmacodynamic effect of PF07258669 compared to placebo in older participants includin…
Pfizer Inc. - A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company · Completed · NCT05463731 - A phase 2, parallel group, randomized, double-blind, placebo-controlle
GlaxoSmithKline, LLC. - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511 - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047444 - A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease
Sage Therapeutics, LLC - A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06047457 - Assessment of safety and efficacy of intravenous remternetug in early symptomatic alzheimers disease
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.